The IAAF would like to remind all athletes, and their support personnel, that the 2017 Prohibited List will come into effect on 1 January 2017. We strongly encourage you to be aware of the changes which have been made by WADA in advance of its introduction in the New Year. Specifically, we recommend to you the four key links or pieces of information below:
- Access the 2017 Prohibited List click here.
- Read the WADA summary of modifications click here.
- Download the Prohibited List iPhone/iPad app click here
(note: currently reflects the 2016 version until January. - The IAAF also encourages all athletes to use resources available from their national anti-doping organisation for further information on the List, and to access useful tools like www.globaldro.com to check whether medications are permitted or prohibited.
Should you require any further assistance in clarifying the list, or have outstanding questions please do not hesitate to contact us on [email protected].
In addition to the information above, the IAAF has provided a short summary of key additions and clarification to the List in 2017 which athletes should be aware of. This information should not replace the need to access or refer to the full prohibited list.
2017 Additions
- GATA inhibitors (e.g., K-11706) and Transforming Growth Factor- β (TGF-β) inhibitors (e.g., sotatercept, luspatercept)
- Lisdexamfetamine is currently prohibited. In 2017 it will be classed as a non-specified stimulant.
- Nicomorphine was added. It is an opioid analgesic drug, which is converted to morphine following administration.
Other important clarifications:
- Salbutamol: Dosing parameters of salbutamol were refined to make it clear that the full 24-hour dose should not be administered at one time; For inhaled salbutamol: maximum 1600 micrograms over 24 hours, not to exceed 800 micrograms every 12 hours.
- Clarification that supplemental oxygen administered intravenously is prohibited, but administration by inhalation is permitted.
- Higenamnie is documented to be a constituent of the plant Tinospora crispa, which can be found in some dietary supplements and is a prohibited non-selective beta-2-agonist.
The following were added to the 2017 Monitoring Programme to establish patterns of use:
- Codeine
- Concurrent use of multiple beta-2-agonists
Clarification on Phenylethylamine: Regular food consumption will not yield sufficient levels of phenylethylamine to result in an Adverse Analytical Finding.
